Efficacy of combination therapy with tacrolimus and mizoribine for cyclophosphamide‐resistant ANCA‐associated glomerulonephritis
- 16 February 2017
- journal article
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 20 (12) , 2214-2216
Abstract
No abstract availableFunding Information
- Astellas Pharma US
- Pfizer
- Chugai Pharmaceutical
- Asahi Kasei Therapeutics Corporation
- Bristol-Myers Squibb
This publication has 10 references indexed in Scilit:
- Tacrolimus successfully used to control refractory eosinophilic granulomatosis with polyangiitis complicated by invasive aspergillosis and chronic hepatitis BInternational Journal of Rheumatic Diseases, 2016
- MicroRNA-30 family members regulate calcium/calcineurin signaling in podocytesJournal of Clinical Investigation, 2015
- Successful Management of Lupus Nephritis with High Titers of Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibodies Using TacrolimusInternal Medicine, 2015
- Successful induction of granulomatosis with polyangiitis with tacrolimusIndian Journal of Nephrology, 2015
- Pathogenesis of Antineutrophil Cytoplasmic Autoantibody–Associated Small-Vessel VasculitisAnnual Review of Pathology: Mechanisms of Disease, 2013
- Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritisClinical and Experimental Nephrology, 2012
- Anti-Neutrophil Antibody Associated Vasculitis in Systemic SclerosisSeminars in Arthritis and Rheumatism, 2011
- Successful Treatment of Class V+IV Lupus Nephritis with Multitarget TherapyJournal of the American Society of Nephrology, 2008
- Mizoribine Corrects Defective Nephrin Biogenesis by Restoring Intracellular Energy BalanceJournal of the American Society of Nephrology, 2007
- Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitisAmerican Journal of Kidney Diseases, 2004